Investigational Drug Details
| Drug ID: | D458 |
| Drug Name: | Manganese |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB06757 |
| DrugBank Description: | Manganese is a transition metal with a molar mass of 54.94g/mol. Manganese is considered critical for human health, and plays important roles in development, metabolism, and the antioxidant system. That said, excessive manganese intake is associated with manganism, a neurodegenerative disorder that causes dopaminergic neuronal death and parkinsonian-like symptoms. |
| PubChem ID: | 27854 |
| CasNo: | 7439-96-5 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [Mn++] |
| Structure: |
|
| InChiKey: | WAEMQWOKJMHJLA-UHFFFAOYSA-N |
| Molecular Weight: | 54.938 |
| DrugBank Targets: | Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial; Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial; TGF-beta-activated kinase 1 and MAP3K7-binding protein 1; Arginase-1; Serotransferrin |
| DrugBank MoA: | |
| DrugBank Pharmacology: | |
| DrugBank Indication: | Indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1273 | NCT01315314 | PHASE4 | COMPLETED | NO | 2005-10 | 2011-03-17 | Details |
| L7054 | NCT00044447 | PHASE3 | COMPLETED | NO | 2001-05 | 2008-06-19 | Details |
| L7208 | NCT05641753 | PHASE4 | RECRUITING | NO | 2022-12-06 | 2025-03-03 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|